crinetics patients

For Patients

Crinetics is focused on the discovery and development of novel therapeutics for rare endocrine diseases and endocrine-related tumors. As part of this mission, we conduct clinical trials to evaluate the safety and efficacy of investigational medicines. If you or someone you know is looking for information about the studies currently underway at Crinetics, you can view the information below, or for questions, contact us at clinicaltrials@crinetics.com.

Ongoing Studies in Acromegaly


CRN00808-02

A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CRN00808 IN PATIENTS WITH ACROMEGALY THAT ARE RESPONDERS TO OCTREOTIDE LAR OR LANREOTIDE DEPOT

crinetics-study_evolve

This Phase 2 study is now recruiting adult patients with acromegaly at participating sites in the United States and Europe. Patients who are treated with Octreotide LAR or Lanreotide Depot as their sole acromegaly medication and have normal IGF-1 levels may be eligible to participate. This study is active and currently recruiting new patients. For more information on this study, please follow the ClinicalTrials.gov link: NCT03792555.


CRN00808-03

AN OPEN LABEL EXPLORATORY STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CRN00808 IN PATIENTS WITH ACROMEGALY TREATED WITH SOMATOSTATIN ANALOGUE BASED TREATMENT REGIMENS

crinetics-study_edge

This phase 2 study is now recruiting adult patients at participating sites in the United States and Europe. Patients who are currently treated with somatostatin-based treatments (e.g. Octreotide, Lanreotide, Pasireotide) may be eligible to participate. This study is active and currently recruiting new patients. For more information on this study, please follow the ClinicalTrials.gov link: NCT03789656.